SCHEMBL2861490

SCHEMBL2861490

O=C(O)c1cnn(Cc2nc(-c3cc(OCCc4ccccc4)cc(C(F)(F)F)c3)cs2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.44
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PPARD Q03181 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
PTGER1 P34995 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CFTR P13569 1/20 0.35
EIF4E P06730 1/20 0.35
S1PR1 P21453 1/20 0.35
S1PR3 Q99500 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
RAB9A P51151 2/20 0.34
CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2860292 0.92 ALDH1A1 (0.42) ALKBH1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL2865997 0.91 MEN1 (0.38) ALKBH1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL2858894 0.88 PPARD (0.39) ALDH1A1KDM4EMEN1KMT2APPARD
SCHEMBL1199101 0.88 ALDH1A1 (0.45) ALDH1A1KDM4EMEN1KMT2AEGLN1
SCHEMBL2857106 0.88 PPARD (0.38) ALDH1A1KDM4EMEN1KMT2APPARD
SCHEMBL2868652 0.87 ALKBH1 (0.45) ALKBH1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL2861404 0.87 MEN1 (0.37) ALDH1A1KDM4EMEN1KMT2APPARD
SCHEMBL1198589 0.87 MMP13 (0.40) ALDH1A1KDM4EMEN1KMT2APPARD
SCHEMBL2859042 0.87 ALKBH1 (0.49) ALKBH1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL2857010 0.87 ALKBH1 (0.48) ALKBH1ALDH1A1KDM4EPPARDEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALKBH1 1916/4885ALDH1A1 1037/4885KDM4E 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.